Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical TrialJAMA 330:512-517, 510, Sims,J.R.,et al, 2023
In Vivo Mapping of Amyloid Toxicity in Alzheimer DiseaseNeurol 72:1504-1511, Frisoni,B.G.,et al, 2009